Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 10/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496428 | 0.89 | CFTR (0.47) | CFTROPRM1OGFRL1ATMMAPKAPK2 | |
| SCHEMBL6278024 | 0.86 | CFTR (0.44) | CFTROPRM1OGFRL1ATMBAZ2B | |
| SCHEMBL6278936 | 0.86 | DRD2 (0.46) | CFTROPRM1OGFRL1MAPKAPK2BAZ2B | |
| SCHEMBL6280942 | 0.85 | CFTR (0.43) | CFTROPRM1OGFRL1ATMKMT2A | |
| SCHEMBL6280948 | 0.85 | CFTR (0.43) | CFTROPRM1OGFRL1MAPKAPK2KMT2A | |
| SCHEMBL6282975 | 0.84 | CFTR (0.45) | CFTROPRM1OGFRL1 | |
| SCHEMBL6280446 | 0.84 | CFTR (0.47) | CFTROPRM1OGFRL1BAZ2B | |
| SCHEMBL6282128 | 0.83 | CFTR (0.47) | CFTRATMACHEMAPKAPK2KMT2A | |
| SCHEMBL6496683 | 0.83 | CFTR (0.46) | CFTROPRM1OGFRL1ATMMAPKAPK2 | |
| SCHEMBL6280730 | 0.82 | CFTR (0.46) | CFTRATMACHEMAPKAPK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | claimed |
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | disclosed |
| WO-2005048916-A2 | TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | GHSR, GHRHR, PRLHR | CFTR 589/4885OPRM1 797/4885OGFRL1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.